Excelra Acquires BISC Global, Creating an International Bioinformatics Powerhouse With an Industry-Leading Platform and Service Offering.
19.4.2023 16:00:00 EEST | Business Wire | Press release
Excelra, a leading life science data and digital solutions provider, has acquired BISC Global, a bioinformatics and data analytics consulting company with offices across Europe and the USA. The acquisition creates an international powerhouse in consulting-led bioinformatics, with expertise in artificial intelligence, machine learning, and omics and next-generation sequencing data analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005464/en/
Excelra is a trusted partner to the world's top pharmaceutical and biotechnology companies, providing data, insight, and R&D technology services. Its interdisciplinary teams of biocurators, bioinformaticians, data scientists, and engineers deliver harmonized data, optimized analysis pipelines, and advanced applications to accelerate drug discovery and development.
BISC Global is a consulting-led platform and service provider specializing in bioinformatics, biostatistics, artificial intelligence, and machine learning. It provides data analysis, pipeline development, cloud computing, and data visualization services. It also offers next-generation platforms such as the Online Pipeline Platform (OP2), which supports streamlined analysis of bulk RNA-seq, single-cell RNA-seq, somatic variant calling, and germline variant calling data; and ImmunoRaptor, an analysis platform that makes it easy for researchers to manage and analyze immune repertoire sequencing data.
BISC Global's leadership believes the acquisition will expand bioinformatics innovation and benefit customers of both organizations. "We are excited about the acquisition by Excelra and are confident that the synergies between our two organizations will enable our consultants to provide best-in-class bioinformatics services to the life science industry," said BISC Global CEO Maarten Braspenning.
Excelra CEO Anandbir Singh Brar said, "The acquisition of BISC Global is a strategic move that enhances our capabilities and expands our reach in the bioinformatics field. The combined entity will be amongst the industry leaders in bioinformatics platforms and services, and will have a major positive impact on the future of bioinformatics and the life science industry."
The acquisition creates a game-changing bioinformatics powerhouse, committed to driving innovation at the intersection of science and technology.
About Excelra
Excelra provides data, insight, and R&D technology services to the world's top pharmaceutical and biotech companies. From offices in Boston, Utrecht, London, and Hyderabad, Excelra's 1000+ domain experts operate at the intersection of science and technology to empower life science innovation and accelerate drug discovery and development. Excelra provides integrated solutions from data to insight. It starts by structuring and harmonizing diverse scientific data sets. Then it builds custom R&D data engineering, cloud infrastructure solutions, tailored computational models, and optimized analysis pipelines to lead the way to groundbreaking discoveries. For more information, visit excelra.com.
About BISC Global
Founded in 2017, BISC Global has grown to be a Top 10 Bioinformatics Consulting and Services Firm, supporting the world's leading pharmaceutical and biotech companies. BISC provides data analytics, custom tool/pipeline development, and cloud solutions delivered on-site or remotely. It has a global workforce of expert consultants, operating from offices in Ghent, Belgium; Basel, Switzerland; Amsterdam, The Netherlands; Boston, MA; and San Francisco, CA. BISC supports analysis across multiple domains, including machine learning (data mining, pattern recognition, image analysis, (un)supervised learning, neural networks, deep learning, etc.), bioinformatics (single-cell transcriptomics, metabolomics, metagenomics, epigenomics, etc.), and statistics (experimental design, mathematic modeling, signal-to-noise enhancement, and independent data cross-validation). For more information, visit biscglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005464/en/
Contact information
Jigesh Shah
Jigesh.shah@excelra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. In DESTINY-Breast09, Enhertu in combination with pertuzumab reduced the risk of disease progression or death by 44% versus a taxan
Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 09:30:00 EEST | Press release
Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO
ADM Club Digitises the Renaissance Court Model Through a Bespoke Technology Stack for Independent Luxury and High Affinity Audiences1.9.2026 09:08:00 EEST | Press release
Alessia Demetz, Founder & CEO of Alesya de Monaco LTD, headquartered in London and the Principality of Monaco, created ADM Club – a business model built on a vertical digital architecture and designed for global scalability – operating at the intersection of luxury craftsmanship and an international network of high-net-worth connoisseurs. This powerful, disruptive vision — bringing hyper-curated craft direct to the customer — translates into digital form the role once played by patrons within Renaissance courts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260821319838/en/ Credits: Photo courtesy of ADM Club. Photography by Martin Morrell. Designed from the outset to enable the model to scale, this architecture supports both the development of the ADM Club network and deployment with international partners, opening the way to collaborations with operators and organisations that reach high-spending audiences. ADM Club is no
Flashnet Partners with Netmore in Strategic Global Partnership for Smart Street Lighting1.9.2026 09:00:00 EEST | Press release
Netmore Group, the leading network operator and platform provider for Massive IoT, today announced that Flashnet, a Lucy Group company and global leader in intelligent street lighting solutions, has joined Netmore's Pulse Partner Program. The partnership marks another important milestone in Netmore's growing ecosystem, combining best-in-class connectivity with proven smart infrastructure solutions to accelerate the digital transformation of cities and utilities around the world. Driven by rapid urbanisation, government sustainability mandates, and the accelerating rollout of smart city programs worldwide, smart street lighting is increasingly recognized as the entry point for smart city transformation and one of the fastest-growing segments of the global IoT infrastructure market. As municipalities and utilities continue to modernize critical infrastructure, this partnership provides a scalable and reliable framework for implementing intelligent street lighting systems that reduce ener
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom